Evidence map›Paper›PMID 37460041›Full record

ArticleCellular and molecular gastroenterology and hepatology2023

Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression.

Greg Malnassy, Claudia R Keating, Shaimaa Gad, Bryan Bridgeman, Aldeb Perera, Wei Hou, Scott J Cotler, Xianzhong Ding, Mashkoor Choudhry, Zhaoli Sun and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Greg MalnassyDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Claudia R KeatingDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Shaimaa GadDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Bryan BridgemanDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Aldeb PereraDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Wei HouDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Scott J CotlerDepartment of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Xianzhong DingDepartment of Pathology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Mashkoor ChoudhryDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois.
Zhaoli SunDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Anthony J KoleskeDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut.
Wei QiuDepartment of Surgery, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois; Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois. Electronic address: wqiu@luc.edu.
Loyola University Chicago · USJohns Hopkins University · USYale University · US

Funding

Molecular mechanisms of focal adhesion kinase in promoting hepatocarcinogenesisR01CA197128 · NCI · LOYOLA UNIVERSITY CHICAGO · PI QIU, WEI · 2015 to 2025
$3.6M
TRAINING IN TRAUMA AND BURN RESEARCHT32GM008750 · NIGMS · LOYOLA UNIVERSITY CHICAGO · PI CHOUDHRY, MASHKOOR A, GONZALEZ, RICHARD PAUL · 2000 to 2023
$2.9M
Impact of excitatory synapse maturation on synaptic plasticity and stabilityR01NS105640 · NINDS · YALE UNIVERSITY · PI HIGLEY, MICHAEL JAMES, KOLESKE, ANTHONY J · 2018 to 2022
$2.5M
Control of Dendritic Spine Stability via Regulation of a Stable Actin PoolR01MH115939 · NIMH · YALE UNIVERSITY · PI KOLESKE, ANTHONY J · 2018 to 2022
$2.2M
Defining the Role of ABL Kinases in Alcoholic Liver DiseaseR21AA028304 · NIAAA · LOYOLA UNIVERSITY CHICAGO · PI QIU, WEI · 2020 to 2021
$400k
NCI NIH HHS R01 CA197128NIAAA NIH HHS R21 AA028304NIGMS NIH HHS T32 GM008750NIMH NIH HHS R01 MH115939NINDS NIH HHS R01 NS105640
6 · The paper itself

Abstract

BACKGROUND &

aimsAlcohol-associated liver disease (ALD) represents a spectrum of alcohol use-related liver diseases. Outside of alcohol abstinence, there are currently no Food and Drug Administration-approved treatments for advanced ALD, necessitating a greater understanding of ALD pathogenesis and potential molecular targets for therapeutic intervention. The ABL-family proteins, including ABL1 and ABL2, are non-receptor tyrosine kinases that participate in a diverse set of cellular functions. We investigated the role of the ABL kinases in alcohol-associated liver disease.

methodsWe used samples from patients with ALD compared with healthy controls to elucidate a clinical phenotype. We established strains of liver-specific Abl1 and Abl2 knockout mice and subjected them to the National Institute on Alcohol Abuse and Alcoholism acute-on-chronic alcohol feeding regimen. Murine samples were subjected to RNA sequencing, AST, Oil Red O staining, H&E staining, Western blotting, and quantitative polymerase chain reaction to assess phenotypic changes after alcohol feeding. In vitro modeling in HepG2 cells as well as primary hepatocytes from C57BL6/J mice was used to establish this mechanistic link of ALD pathogenesis.

resultsWe demonstrate that the ABL kinases are highly activated in ALD patient liver samples as well as in liver tissues from mice subjected to an alcohol feeding regimen. We found that the liver-specific knockout of Abl2, but not Abl1, attenuated alcohol-induced steatosis, liver injury, and inflammation. Subsequent RNA sequencing and gene set enrichment analyses of mouse liver tissues revealed that relative to wild-type alcohol-fed mice, Abl2 knockout alcohol-fed mice exhibited numerous pathway changes, including significantly decreased peroxisome proliferator activated receptor (PPAR) signaling. Further examination revealed that PPARγ, a previously identified regulator of ALD pathogenesis, was induced upon alcohol feeding in wild-type mice, but not in Abl2 knockout mice. In vitro analyses revealed that shRNA-mediated knockdown of ABL2 abolished the alcohol-induced accumulation of PPARγ as well as subsequent lipid accumulation. Conversely, forced overexpression of ABL2 resulted in increased PPARγ protein expression. Furthermore, we demonstrated that the regulation of hypoxia inducible factor 1 subunit alpha (HIF1α) by ABL2 is required for alcohol-induced PPARγ expression. Furthermore, treatment with ABL kinase inhibitors attenuated alcohol-induced PPARγ expression, lipid droplet formation, and liver injury.

conclusionsOn the basis of our current evidence, we propose that alcohol-induced ABL2 activation promotes ALD through increasing HIF1α and the subsequent PPARγ expression, and ABL2 inhibition may serve as a promising target for the treatment of ALD.

Indexed as

Liver Diseases, AlcoholicPPAR gammaAnimalsEthanolHumansMiceMice, KnockoutTyrosineEthanolPPAR gammaTyrosineABL2Alcohol-Associated Liver DiseaseHIF1αNilotinibPPARγ

Identifiers

PMID37460041
PMCPMC10520367
OpenAlexW4384408366

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.